ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SU-OR32

Complement C5a Receptor Inhibitor Avacopan Improves Renal Function in ANCA Vasculitis

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Jayne, David R.W., Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
  • Merkel, Peter A., University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Yue, Huibin, ChemoCentryx Inc, Mountain View, California, United States
  • Kelleher, Catherine L., ChemoCentryx Inc, Mountain View, California, United States
  • Schall, Thomas J., ChemoCentryx Inc, Mountain View, California, United States
  • Bekker, Pirow, ChemoCentryx Inc, Mountain View, California, United States

Renal impairment is common in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The resulting chronic kidney disease and exacerbation of the toxicity risks of high dose or prolonged glucocorticoid use, a mainstay of ANCA treatment, are major consequences. Avacopan was tested for efficacy and effects on renal function compared to standard prednisone therapy in a randomized double-blind Phase 3 trial in ANCA vasculitis.


Subjects randomized 1:1 received either prednisone (60 mg tapered to 0 over 20 weeks) or avacopan (30 mg twice daily for 52 weeks), combined with either cyclophosphamide (CYC) followed by azathioprine, or rituximab (RTX). Primary endpoints: Disease remission at week 26 and sustained remission at week 52. Changes in urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were also assessed.


330 subjects were treated: 166 to avacopan and 164 to prednisone treatment groups. Avacopan remission at week 26 was 72.3% vs. 70.1%, for prednisone (P<0.0001 for non-inferiority); avacopan was superior to prednisone for sustained remission (week 52, 65.7%, avacopan vs. 54.9%, prednisone, P=0.0066).
81% percent of subjects had renal disease. UACR decreased more rapidly with avacopan than prednisone: week 4 avacopan was 40% below baseline vs. no change for prednisone (P<0.0001). Baseline to week 52 eGFR (mL/min/1.73 m2) improvement: avacopan eGFR +7.3 vs. prednisone +4.1 (P=0.029). In subjects with baseline eGFR <30: mean eGFR improved 67% more with avacopan than prednisone to week 52: avacopan eGFR +13.7 vs. prednisone +8.2 (P=0.01).


Treatment with avacopan for ANCA vasculitis compared with standard glucocorticoid therapy (both combined with either CYC or RTX) is as effective for remission induction at 26 weeks, and superior to prednisone for sustained remission after 52 weeks. Avacopan led to faster falls in UACR and greater recovery in eGFR when compared to standard prednisone therapy. These findings have important implications for the long term health of AAV patients through better overall disease control, reduced prednisone exposure and reduced severity of chronic kidney disease.


  • Commercial Support